FINDEX’s Software Growth Holds Steady as It Doubles Down on AI and Dividends

FINDEX Inc. said its hospital, clinic and government software base kept growing as of June 30, but the company also trimmed how much it was willing to show. The Tokyo-listed firm, ticker 3649, saw Claio, DocuMaker and several other products add users while its generative-AI subsidiary, CocktailAI, took a bigger share of the spotlight.

FINDEX’s growth is real but incremental. The company also narrowed which products it discloses to what management calls its clearest indicators of future performance, and leaned harder on CocktailAI and a fast-rising dividend, even as its own guidance calls for barely 2% sales growth this year.

FINDEX Reports Broad Gains Across Its Hospital Software Lineup

The June 30 disclosure covers the tools FINDEX now calls its clearest signal of where the business is headed. Claio, its image and data filing platform, along with the DocuMaker document system and the C-Scan archiving tool, all added net institutional users across university hospitals, general hospitals and clinics.

REMORA, the company’s electronic medical record system, picked up new hospital customers. PiCls, its cloud services brand for large-hospital collaboration, widened its reach too. DocuMaker Office, the version built for city halls and prefectural offices, kept adding local government users, and the GAP gaze-analyzing perimeter, an in-house visual field testing device, shipped in additional volumes.

Every row moved in the same direction. None of it reads as a slowdown, and none of it reads as a breakout quarter either.

A Narrower Scorecard, and a Bigger Role for AI

Management called the shorter list a matter of focus. FINDEX said the disclosed products are the ones it now considers the clearest markers of where its business is headed, and it used the same release to elevate CocktailAI, the generative-AI tool built by its subsidiary Fitting Cloud Inc.

The contrast with FINDEX’s own earlier disclosures is easy to spot. Its report on year-end 2025 implementation figures gave a hard number for the GAP perimeter: 213 units shipped. Six months later, the same device gets one word: incremental.

That June 30 update was also the fifth FINDEX disclosure of the year, and the pattern behind it is worth laying out in order.

1. January 20, 2026: FINDEX discloses year-end 2025 implementation figures, including 213 GAP units shipped and an analyst Buy rating carrying a ¥1,156 price target.
2. February 13, 2026: The company unveils its 2026 to 2030 Growth Strategy and Shareholder Return Policy, lifting its target payout ratio.
3. May 14, 2026: FINDEX posts first-quarter results, holds its full-year guidance and lifts its dividend to ¥27 per share.
4. June 26, 2026: FINDEX confirms a 13 yen interim dividend with a June 29 ex-dividend date and a June 30 record date.
5. June 30, 2026: FINDEX issues the narrowed implementation update at the center of this story, spotlighting CocktailAI.

Four of those five announcements landed inside six months. Each one nudged the dividend story or the AI narrative a step further, ending in a report that names fewer products than the one it replaced.

Why Hospitals and City Halls Keep Buying In

The demand behind these gains traces back to a labor rule most readers outside Japan have never heard of. Overtime caps on physicians took effect in April 2024, part of a broader push toward shifting paperwork away from doctors themselves. FINDEX built its document and archiving tools around exactly that pressure point.

DocuMaker Office, the version FINDEX sells to city halls and prefectural governments, sits in a market the company itself describes as thin on rivals. Its investor materials say FINDEX is expanding from municipalities toward national agencies on the back of that advantage.

On the hospital side, REMORA and Claio ride a separate government push. Japan’s Next-Generation Medical Infrastructure Act encourages certified operators to pool anonymized medical record data, and FINDEX has positioned its systems as the compliant plumbing underneath that pipeline.

CocktailAI Has Receipts Beyond the Buzzword

CocktailAI is not a name management invented for this update. FINDEX’s subsidiary Fitting Cloud Inc. built the tool specifically to draft medical documents using generative AI, and it already has a two-year public track record.

The product was featured at Google for Japan 2024, where Kyoto University Hospital professor Tomohiro Kuroda spoke about AI’s role in Japan’s health system. CocktailAI grew out of joint research between Fitting Cloud and the hospital.

That track record gives the CocktailAI bet real backing: an outside award from Google Cloud’s Generative AI Innovation Awards, an academic hospital partner, and two years of public visibility before this week’s update.

The Payout Bet Outpaces Sales Growth

FINDEX laid out its wager in February, unveiling a five-year growth and shareholder return plan covering 2026 through 2030. The headline is the payout ratio, which the company is raising from 30% to a target of 50% of profit.

• Payout ratio climbs from 30% to a target of 50% of profit.
• Dividend floor set at an 8.5% Dividend on Equity, guaranteeing a minimum payout regardless of profit swings.
• Treasury shares earmarked for restricted stock and J-ESOP incentive programs, a Japanese employee stock ownership trust structure.
• Dividend per share projected to rise from ¥27 in fiscal 2026 to ¥48 by fiscal 2030.

That is close to a doubling of the per-share payout inside five years. It sits on top of guidance FINDEX reaffirmed in its first-quarter results in May, when the company kept its full-year target at 1.6% net sales growth and a 3.6% rise in profit attributable to owners of the parent.

FINDEX is betting shareholders will take steady cash now over a bigger growth number later.

Is FINDEX Stock Still Rated a Buy?

Yes, on the technical side: FINDEX carries a Strong Buy technical sentiment signal, average trading volume near 93,046 shares, and a market capitalization of roughly ¥23.1 billion, or about $150 million at current exchange rates. Shares have swung between ¥666 and ¥1,228 over the past year, a wide range for a company guiding to barely 2% sales growth. FINDEX trades on the Prime Market, the Tokyo Stock Exchange’s tier for larger listed companies.

The fundamentals underneath that signal are thinner. FINDEX posted EBITDA of roughly ¥1.82 billion on a 31% margin, and its most recent quarterly net income jumped to ¥330.74 million from ¥130.30 million the quarter before, a 153.84% swing, according to TradingView data.

FINDEX is not alone in stretching an AI narrative over steadier fundamentals. Oracle’s cloud arm is carrying a $638 billion order backlog that cuts both ways, a dynamic playing out from small Japanese software makers to the largest cloud providers.

Five analysts cover FINDEX stock, though only one has submitted the estimates behind its consensus revenue and earnings figures.

Frequently Asked Questions

What Is CocktailAI, and Who Makes It?

CocktailAI is a generative-AI tool built by Fitting Cloud Inc., a FINDEX subsidiary, to help draft medical documents automatically. FINDEX has also been folding generative AI into DocuMaker itself, a separate push aimed at easing physician paperwork that the company said in 2024 had already been adopted by many customers.

What Does FINDEX’s GAP Device Actually Do?

GAP is a portable, head-mounted visual field testing device for early glaucoma detection. FINDEX’s own investor materials say it needs no darkened exam room and can cut a test that once took over ten minutes down to three to five minutes.

Where Does FINDEX Sell Outside Japan?

FINDEX describes itself as being in the early stage of international expansion, with sales underway in the European Union, Taiwan and South America, according to its investor materials.

Who Are FINDEX’s Closest Public Comparables?

Yahoo Finance lists Medical Data Vision Co. and Vitalhub Corp. among the companies most comparable to FINDEX, both of which also build data and record-keeping software for healthcare providers.

Is FINDEX’s Dividend Increase Backed by Profit Growth?

The dividend has been rising for several years already. FINDEX’s dividend yield reached 1.75% in 2024 with a payout ratio of 33.12%, up from 1.26% and 31.47% a year earlier, according to TradingView data, before the new 2026 to 2030 targets were even announced.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. FINDEX Inc. trades on the Tokyo Stock Exchange under ticker 3649, and stock prices, dividend policies and analyst ratings referenced here are subject to change. Figures are accurate as of publication, and readers should consult a licensed financial professional before making investment decisions.